<\/p>\n
For decades, a pancreatic cancer diagnosis came with almost no good options. <\/p>\n
The disease is usually caught late, spreads fast, and resists most treatments. Patients and their families were often left with months, not years.<\/p>\n
That grim picture just changed.<\/p>\n
On Aug. 26, the U.S. Food and Drug Administration approved Rasonque daraxonrasib, a once-daily pill from Revolution Medicines (RVMD). <\/p>\n
It is the first broad RAS-targeted medicine cleared for adults with metastatic pancreatic cancer who have already had chemotherapy.<\/p>\n
For investors, the approval turns a research-stage company into one with a product on pharmacy shelves. The stock reaction, though, was quieter than you might expect.<\/p>\n
What Revolution Medicines’ Rasonque does that older drugs could not<\/p>\n
Most pancreatic tumors are driven by a mutated protein called RAS. When RAS goes wrong, it tells cancer cells to keep growing.<\/p>\n
RAS mutations show up in over 90% of pancreatic cancer cases, which made the protein one of the most important targets in cancer research, according to NPR. <\/p>\n
It was also one of the hardest to hit, and drugmakers spent years trying and failing.<\/p>\n
More Healthcare Stocks:<\/p>\n
Merck adds $43 billion after cancer vaccine trial win<\/p>\n
BofA biotech scorecard: Two buys and one odd one out<\/p>\n
Federal court hands Gilead a win that protects its top HIV drug<\/p>\n
Rasonque attacks several forms of mutated RAS directly. The results were striking.<\/p>\n
In the RASolute 302 Phase 3 trial of 500 previously treated patients, the drug nearly doubled median overall survival to 13.2 months, up from 6.7 months on standard chemotherapy, according to the FDA. <\/p>\n
It also cut the risk of death by 60%.<\/p>\n
The drug is not a cure, and doctors are clear about that. It buys patients more time, which for this cancer is a meaningful shift.<\/p>\n
Why the FDA cleared the pancreatic cancer drug so fast<\/p>\n
The speed of this approval stood out almost as much as the data.<\/p>\n
The FDA cleared Rasonque about five weeks, or 35 days, after accepting the application, BioPharma Dive reported. A typical review runs 10 to 12 months.<\/p>\n
Revolution moved through the FDA’s Commissioner’s National Priority Voucher program, which fast-tracks drugs that address major public health needs. <\/p>\n
The drug also carried Breakthrough Therapy and Orphan Drug designations.<\/p>\n
Before full approval, more than 2,000 patients had already received the drug through an expanded access program, Reuters confirmed.<\/p>\n
That head start matters for revenue, because those patients form a ready base of early demand.<\/p>\n
The FDA’s approval of Rasonque gives adults with previously treated metastatic pancreatic cancer the first broad RAS-targeted pill, nearly doubling median survival in its trial.<\/p>\n
Win McNamee \/ Getty Images<\/p>\n
How the approval reshapes RVMD’s business<\/p>\n
Until this week, Revolution Medicines earned no product revenue. <\/p>\n
It was a clinical-stage company living off its balance sheet, which held $3.9 billion in cash as of June 30, according to MedCity News.<\/p>\n
Now it has a commercial drug and a price tag to match. Revolution set the wholesale cost at $39,800 for a 30-day supply, CNN reported. <\/p>\n
Some commercially insured patients could pay as little as $0 through co-pay assistance.<\/p>\n
Analysts at RBC Capital Markets laid out how sales could ramp.<\/p>\n
RBC’s early sales forecast for Rasonque<\/p>\n
Third quarter 2026: About $28 million in U.S. revenue<\/p>\n
Fourth quarter 2026: Roughly $148 million<\/p>\n
Peak annual sales: An estimated $11.5 billion over the long term<\/p>\n
Those figures explain why investors were watching this approval so closely.<\/p>\n
Why RVMD stock barely moved on historic news<\/p>\n
Here is the part that surprises people. Despite landmark data and a fast approval, RVMD shares stayed roughly flat near $211.70 on the day, CNN noted.<\/p>\n
The reason is simple. The market already knew.<\/p>\n
Rasonque’s trial data was widely presented at oncology conferences earlier this year, and investors bought in ahead of the news. <\/p>\n
That buying pushed the stock up 166% in 2026 before the FDA even ruled. By approval day, the good news was largely priced into the shares. <\/p>\n
As of Aug. 27, RVMD traded around $218, up about 1% from the prior close.<\/p>\n
The risks RVMD investors should watch next<\/p>\n
The approval clears one hurdle. However, several others remain, and they will shape whether the $11.5 billion sales dream holds up.<\/p>\n
Insurance coverage is the big one. At nearly $40,000 a month, commercial success depends heavily on how quickly private insurers and Medicare agree to pay. Some investors are already focused on that question.<\/p>\n
Competition is building. Rival Erasca is developing its own RAS-targeting candidates, which creates long-term market share risk.<\/p>\n
Related: UBS strongly resets Lilly stock target<\/p>\n
Pipeline execution still counts. Revolution is testing Rasonque as a first-line pancreatic cancer treatment and studying zoldonrasib, an experimental pancreatic cancer candidate aimed at a specific RAS mutation. <\/p>\n
The company is also studying Rasonque in lung cancer, which could expand the market well beyond today’s approval.<\/p>\n
What this means for your portfolio<\/p>\n
If you already own RVMD, the approval validates the core thesis. The company now sells a product, and the science works.<\/p>\n
If you are considering the stock, the setup is trickier. Much of the good news is already in the price, so new buyers are betting on execution rather than a new surprise.<\/p>\n
A few things worth tracking before Revolution’s next earnings report.<\/p>\n
Key signals to watch for Rasonque’s launch<\/p>\n
Early coverage decisions from major insurers and Medicare<\/p>\n
Third-quarter sales, due to give the first real read on demand<\/p>\n
Progress in the first-line pancreatic and lung cancer trials<\/p>\n
None of these is guaranteed, and biotech stocks can swing hard on a single trial result or coverage decision. <\/p>\n
Anyone buying RVMD should size the position to their own risk tolerance and remember that even a strong stock can see sharp pullbacks when expectations run this high.<\/p>\n
The broader takeaway reaches past one stock. After years of dead ends, researchers finally cracked one of cancer’s toughest targets, and that opens the door for more RAS-based medicines across other tumors.<\/p>\n
Revolution Medicines spent years chasing a target most of the industry had given up on. This week, that patience paid off for patients first and shareholders second.<\/p>\n
Related: 135-year-old healthcare giant surges on cancer vaccine breakthrough<\/p>\n
#Patients #deadliest #cancer #finally #works<\/p>\n","protected":false},"excerpt":{"rendered":"
For decades, a pancreatic cancer diagnosis came with almost no good options. The disease is…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[989,20376,1106,9423,2605],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/14819"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14819"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/14819\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}